APLS
Price
$18.26
Change
+$0.44 (+2.47%)
Updated
Jul 3 closing price
Capitalization
2.29B
36 days until earnings call
BPMC
Price
$128.35
Change
+$0.15 (+0.12%)
Updated
Jul 3 closing price
Capitalization
8.29B
24 days until earnings call
Interact to see
Advertisement

APLS vs BPMC

Header iconAPLS vs BPMC Comparison
Open Charts APLS vs BPMCBanner chart's image
Apellis Pharmaceuticals
Price$18.26
Change+$0.44 (+2.47%)
Volume$891.12K
Capitalization2.29B
Blueprint Medicines
Price$128.35
Change+$0.15 (+0.12%)
Volume$1.35M
Capitalization8.29B
APLS vs BPMC Comparison Chart in %
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. BPMC commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and BPMC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (APLS: $18.26 vs. BPMC: $128.35)
Brand notoriety: APLS and BPMC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 35% vs. BPMC: 37%
Market capitalization -- APLS: $2.29B vs. BPMC: $8.29B
APLS [@Biotechnology] is valued at $2.29B. BPMC’s [@Biotechnology] market capitalization is $8.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileBPMC’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • BPMC’s FA Score: 0 green, 5 red.
According to our system of comparison, BPMC is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 5 TA indicator(s) are bullish while BPMC’s TA Score has 3 bullish TA indicator(s).

  • APLS’s TA Score: 5 bullish, 4 bearish.
  • BPMC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, APLS is a better buy in the short-term than BPMC.

Price Growth

APLS (@Biotechnology) experienced а -0.76% price change this week, while BPMC (@Biotechnology) price change was +0.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

APLS is expected to report earnings on Aug 11, 2025.

BPMC is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BPMC($8.29B) has a higher market cap than APLS($2.3B). BPMC YTD gains are higher at: 47.157 vs. APLS (-42.777). BPMC has higher annual earnings (EBITDA): -66.42M vs. APLS (-176.08M). BPMC has more cash in the bank: 576M vs. APLS (358M). BPMC (467M) and APLS (470M) have identical debt. APLS has higher revenues than BPMC: APLS (776M) vs BPMC (562M).
APLSBPMCAPLS / BPMC
Capitalization2.3B8.29B28%
EBITDA-176.08M-66.42M265%
Gain YTD-42.77747.157-91%
P/E RatioN/AN/A-
Revenue776M562M138%
Total Cash358M576M62%
Total Debt470M467M101%
FUNDAMENTALS RATINGS
APLS vs BPMC: Fundamental Ratings
APLS
BPMC
OUTLOOK RATING
1..100
5060
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
10054
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
8640
P/E GROWTH RATING
1..100
10066
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APLS's Valuation (70) in the Medical Distributors industry is in the same range as BPMC (81) in the Biotechnology industry. This means that APLS’s stock grew similarly to BPMC’s over the last 12 months.

BPMC's Profit vs Risk Rating (54) in the Biotechnology industry is somewhat better than the same rating for APLS (100) in the Medical Distributors industry. This means that BPMC’s stock grew somewhat faster than APLS’s over the last 12 months.

BPMC's SMR Rating (97) in the Biotechnology industry is in the same range as APLS (98) in the Medical Distributors industry. This means that BPMC’s stock grew similarly to APLS’s over the last 12 months.

BPMC's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for APLS (86) in the Medical Distributors industry. This means that BPMC’s stock grew somewhat faster than APLS’s over the last 12 months.

BPMC's P/E Growth Rating (66) in the Biotechnology industry is somewhat better than the same rating for APLS (100) in the Medical Distributors industry. This means that BPMC’s stock grew somewhat faster than APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSBPMC
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
83%
Momentum
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
71%
Advances
ODDS (%)
Bullish Trend 27 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
79%
Bearish Trend 10 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
65%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BLOK59.110.16
+0.27%
Amplify Transformational Data Shrg ETF
FPXE30.940.07
+0.24%
First Trust IPOX Europe Equity Opps ETF
NCZ12.850.02
+0.16%
Virtus Convertible & Income Fund II
GPRF50.53N/A
N/A
Goldman Sachs Acs US Pref Stk &HySecETF
MSTI20.59-0.03
-0.17%
Madison Short-Term Strategic Income ETF

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+2.47%
ROIV - APLS
45%
Loosely correlated
+0.18%
BPMC - APLS
44%
Loosely correlated
+0.12%
ARWR - APLS
44%
Loosely correlated
-0.65%
EYPT - APLS
43%
Loosely correlated
+0.62%
DNLI - APLS
43%
Loosely correlated
-1.41%
More

BPMC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with KYMR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BPMC
1D Price
Change %
BPMC100%
+0.12%
KYMR - BPMC
49%
Loosely correlated
+0.58%
VERA - BPMC
47%
Loosely correlated
+1.48%
NRIX - BPMC
45%
Loosely correlated
+2.33%
APLS - BPMC
44%
Loosely correlated
+2.47%
IDYA - BPMC
43%
Loosely correlated
+0.82%
More